CV vs POSC vs HTFL Stock Comparison

CapsoVision, Positron and Heartflow Prices as of Oct 27, 2026 Peers: Industry group
CV CapsoVision, Inc
$6.75 +1.5% 1M +38.9% 1Y
Market cap
$343.57M
P/E
–
Revenue (TTM)
$14.41M
Div. yield
–
Diagnostic Equipment Healthcare
POSC Positron Corp
$1.72 -7.0% 1M +14.7% 1Y
Market cap
$56.50M
P/E
–
Revenue (TTM)
$462.27K
Div. yield
–
Diagnostic Equipment Healthcare
1 win
HTFL Heartflow, Inc.
$57.82 +17.6% 1M +50.8% 1Y
Market cap
$5.16B
P/E
–
Revenue (TTM)
$202.91M
Div. yield
–
Diagnostic Equipment Healthcare
5 wins

Head to Head

6 decided of 12

Heartflow leads on 5 of the 12 questions below (Heartflow 5, Positron 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCVPOSCHTFLLeader
Larger companyMarket capitalisation $343.57M $56.50M $5.16B HTFL
Cheaper on earningsLower P/E, profitable companies only -12.5x -11.5x -51.5x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — — — –
Faster revenue growthRevenue growth, trailing twelve months +14.6% +202.2% +42.5% POSC
More profitableNet margin, trailing twelve months -190.2% -1,060.5% -49.4% HTFL
Better return on capitalReturn on invested capital — — — –
Less leveragedLower net debt / EBITDA — -0.3x — –
Higher dividend yieldTrailing dividend yield 0.00% — 0.00% –
Better 1-year returnPrice return, last 12 months +38.9% +14.7% +50.8% HTFL
Better 5-year returnAnnualised price return, 5 years — +23.5%/yr — –
Less volatileAnnualised volatility, 1 year 96.0% 86.7% 76.7% HTFL
Higher overall scoreMean of the five percentile scores vs peers 37/100 13/100 57/100 HTFL

Percentile Scorecard

CVPOSCHTFL

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCVPOSCHTFL
Valuation 5 #216 of 227 21 #180 of 227 9 #207 of 227
Growth 44 #123 of 219 19 #178 of 219 78 #49 of 219
Profitability 23 #159 of 206 4 #197 of 206 49 #106 of 206
Financial Health 76 #58 of 238 4 #228 of 238 92 #20 of 238
Shareholder Returns – 19 #109 of 134 –
Overall 37 13 57
  • CV ranked among 247 companies in Medical Devices and Diagnostics
  • POSC ranked among 247 companies in Medical Devices and Diagnostics
  • HTFL ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCVPOSCHTFLSPY
1 month +1.5%-7.0%+17.6% -0.2%
3 months +2.0%+7.5%+125.9% +3.9%
6 months -0.4%-7.0%+89.3% +8.2%
Year to date -36.9%+3.0%+98.4% +12.9%
1 year +38.9%+14.7%+50.8% +12.3%
3 years —+37.6%— +87.4%
3 years, per year —+11.2%— +23.3%
5 years —+186.7%— +67.9%
5 years, per year —+23.5%— +10.9%
10 years —+5,633.3%— +261.1%
10 years, per year —+49.9%— +13.7%

Risk

MeasureCVPOSCHTFLSPY
Volatility, 1Y 96.0%86.7%76.7% 12.7%
Downside volatility, 1Y 89.4%87.5%77.5% 12.7%
Beta vs S&P 500, 1Y 0.610.281.90 1.00
Return / volatility, 1Y 0.410.170.66 0.97
Max drawdown, 5Y -67.8%-65.6%-48.7% -25.4%
From 52-week high -53.2%-32.8%0.0% -1.2%
52-week high $14.42$2.56$57.82 $779.14
52-week low $4.59$1.31$20.49 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCVPOSCHTFL
P/E now vs peer median -12.3xmedian 29.6x -11.5xmedian 29.6x -49.9xmedian 29.6x
P/S now vs peer median 23.4xmedian 2.9x 122.2xmedian 2.9x 24.7xmedian 2.9x
EV/EBITDA now vs peer median -12.3xmedian 17.4x -12.2xmedian 17.4x —median 17.4x
P/FCF now vs peer median —median 22.3x -13.6xmedian 22.3x —median 22.3x
P/B now vs peer median 25.7xmedian 2.3x -85.5xmedian 2.3x 17.9xmedian 2.3x
PEG now vs peer median —median 1.04 —median 1.04 —median 1.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCVPOSCHTFL
Revenue $14.41M $462.27K $202.91M
Gross profit $7.55M -$1.33M $160.45M
Operating income -$27.71M -$4.82M -$64.46M
Net income -$27.42M -$4.90M -$100.19M
Free cash flow – -$4.16M –
R&D $20.51M – $77.26M
EPS (diluted) $-0.55 $-0.15 $-1.16
Cash & equivalents – $357.17K $34.36M
Total debt – $2.00M –
Shares (diluted) 49.94M 32.85M 86.40M
Enterprise value $343.57M $49.22M $4.91B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCVPOSCHTFL
P/E -12.3x -11.5x -49.9x
P/FCF – -13.6x –
P/Operating cash flow – -13.6x –
P/S 23.4x 122.2x 24.7x
P/B 25.7x -85.5x 17.9x
P/Tangible book 25.7x -85.5x 17.9x
EV/EBITDA -12.3x -12.2x –
EV/EBIT -12.2x -12.1x -74.0x
EV/Revenue 23.4x 125.8x 23.5x
EV/FCF – -14.0x –
EV/Operating cash flow – -14.0x –
PEG (3Y EPS CAGR) – – –

Growth

14 metrics
MetricCVPOSCHTFL
Revenue growth (1Y) 14.6% 202.2% 42.5%
Revenue CAGR (3Y) – – –
Gross profit growth (1Y) 11.1% -15.2% 48.8%
Gross profit CAGR (3Y) – – –
Operating income growth (1Y) -36.1% -17.5% -9.5%
Operating income CAGR (3Y) – – –
Net income growth (1Y) -34.9% -18.0% -18.3%
Net income CAGR (3Y) – – –
EPS growth (1Y) 93.8% -12.5% 91.4%
EPS CAGR (3Y) – – –
Operating cash flow growth (1Y) – -17.0% –
Operating cash flow CAGR (3Y) – – –
Free cash flow growth (1Y) – -17.0% –
Free cash flow CAGR (3Y) – – –

Profitability

14 metrics
MetricCVPOSCHTFL
Gross margin 52.4% -288.1% 79.1%
EBITDA margin -190.7% -1,030% –
Operating margin -192.3% -1,042% -31.8%
Pretax margin -190.1% -1,060% -49.4%
Net margin -190.2% -1,060% -49.4%
FCF margin – -900.4% –
Operating cash flow margin – -900.4% –
Return on equity -207.5% – -34.5%
Return on assets -149.3% -216.9% -28.5%
Return on invested capital – – –
Return on capital employed -209.8% -61,094% -20.9%
Asset turnover 0.8x 0.2x 0.6x
Cash conversion (OCF / net income) – 0.8x –
Stock comp / revenue – – 9.6%

Financial Health

11 metrics
MetricCVPOSCHTFL
Debt / assets – 115.8% –
Debt / equity – -3.0x –
Net debt / EBITDA – -0.3x –
Debt / FCF – -0.5x –
Liabilities / assets 29.1% 138.2% 18.8%
Equity / assets 70.9% -38.2% 81.2%
Interest coverage – -43.8x –
Current ratio 3.4x 0.5x 5.1x
Quick ratio – 0.2x 6.6x
Cash ratio – 0.2x 5.6x
Altman Z-score 21.31 -114.72 42.47

Shareholder Returns

7 metrics
MetricCVPOSCHTFL
Dividend yield – – –
Net buyback yield – -5.3% –
Shareholder yield 0.0% -5.3% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCVPOSCHTFL
EPS, next fiscal year $-0.58FY2026 – $-0.43FY2026
Revenue, next fiscal year $13.91MFY2026 – $261.38MFY2026
Revenue growth, next FY +2.7%FY2026 – +48.5%FY2026
Revenue growth, the year after +46.0% – +20.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCVPOSCHTFL
Held by institutions 10.2% – 100.0%
Institutions holding 50 – 192
Change in shares held, QoQ +27.6% – +133.0%
Institutions buying 36 – 140
Institutions selling 8 – 38
Buyers to sellers 4.50 – 3.68

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CVPOSCHTFL
CV 1.00 0.01 0.04
POSC 0.01 1.00 0.08
HTFL 0.04 0.08 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CV, POSC and HTFL?

Heartflow (HTFL) is the largest by market capitalisation: CapsoVision (CV) $343.57M, Positron (POSC) $56.50M, Heartflow (HTFL) $5.16B.

Which company is growing faster?

Positron (POSC) grew revenue fastest over the trailing twelve months: CapsoVision (CV) +14.6%, Positron (POSC) +202.2%, Heartflow (HTFL) +42.5%.

Which company is more profitable?

Heartflow (HTFL) has the highest net margin (CapsoVision (CV) -190.2%, Positron (POSC) -1,060.5%, Heartflow (HTFL) -49.4%).

Which stock has performed better?

Over the past year Heartflow (HTFL) returned the most: CapsoVision (CV) +38.9%, Positron (POSC) +14.7%, Heartflow (HTFL) +50.8%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Heartflow (HTFL) has been the steadiest (CapsoVision (CV) 96.0%, Positron (POSC) 86.7%, Heartflow (HTFL) 76.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CV, POSC and HTFL?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Heartflow (HTFL) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.